Lakewood-Amedex Biotherapeutics, Inc. (LABT) Financials
LABT Assets vs Liabilities
| Date | Assets | Liabilities |
|---|---|---|
| June 30, 2026 | 5.0 million | 628926 |
| March 31, 2026 | 196343 | 3.0 million |
| Dec. 31, 2025 | 481598 | 2.4 million |
| Sept. 30, 2025 | 985118 | 2.3 million |
LABT Free Cash Flow and Stock based compensation
Graph available only for paid members. Upgrade to see it.
| Date | Free Cash Flow | Stock based compensation |
|---|---|---|
| June 30, 2026 | -2.1 million | 61245 |
| March 31, 2026 | -349691 | 46180 |
| Dec. 31, 2025 | -422010 | 46697 |
| Sept. 30, 2025 | -610045 | 1.2 million |
LABT Net Income
No data available :(
LABT Cash and Debt
Graph available only for paid members. Upgrade to see it.
| Date | Cash | Debt | Capital Lease |
|---|---|---|---|
| June 30, 2026 | 4.6 million | - | - |
| March 31, 2026 | 11709 | - | 131339 |
| Dec. 31, 2025 | 236400 | - | 160341 |
| Sept. 30, 2025 | 658410 | - | 189018 |
LABT Shares Outstanding
LABT Expenses
Graph available only for paid members. Upgrade to see it.
| Date | Capex | R&D | G&A | S&M |
|---|---|---|---|---|
| June 30, 2026 | - | 503020 | 3.3 million | - |
| March 31, 2026 | - | 182147 | 703444 | - |
| Dec. 31, 2025 | - | 185730 | 525172 | 36490 |
| Sept. 30, 2025 | - | 752931 | 1.1 million | - |
LABT Cost of Revenue
Graph available only for paid members. Upgrade to see it.
| Date | Revenue | Cost of Revenue |
|---|---|---|
| June 30, 2026 | - | - |
| March 31, 2026 | - | - |
| Dec. 31, 2025 | - | 30290 |
| Sept. 30, 2025 | - | - |
LABT
Price: $0.58
52 week price:
Earnings Per Share: -2.41 USD
Exchange: NGM
Sector: Healthcare
Industry: Biotechnology
Market Capitalization: 1.5 million